Phoenix Financial Ltd. Sells 853,573 Shares of Cellebrite DI Ltd. (NASDAQ:CLBT)

Phoenix Financial Ltd. lessened its stake in Cellebrite DI Ltd. (NASDAQ:CLBT) by 37.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,413,424 shares of the company’s stock after selling 853,573 shares during the quarter. Phoenix Financial Ltd.’s holdings in Cellebrite DI were worth $31,138,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the business. Renaissance Technologies LLC increased its position in shares of Cellebrite DI by 7.7% during the 4th quarter. Renaissance Technologies LLC now owns 1,630,439 shares of the company’s stock valued at $35,919,000 after purchasing an additional 115,939 shares during the last quarter. Legal & General Group Plc grew its stake in shares of Cellebrite DI by 30.0% during the fourth quarter. Legal & General Group Plc now owns 160,223 shares of the company’s stock valued at $3,530,000 after buying an additional 36,949 shares during the last quarter. Invesco Ltd. bought a new stake in Cellebrite DI during the 4th quarter valued at $32,700,000. FMR LLC boosted its stake in shares of Cellebrite DI by 89.1% during the 4th quarter. FMR LLC now owns 10,621,344 shares of the company’s stock valued at $233,988,000 after purchasing an additional 5,004,587 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its position in shares of Cellebrite DI by 191.6% during the fourth quarter. Russell Investments Group Ltd. now owns 150,416 shares of the company’s stock valued at $3,314,000 after buying an additional 98,833 shares during the last quarter. 45.88% of the stock is currently owned by institutional investors and hedge funds.

Cellebrite DI Stock Performance

NASDAQ:CLBT opened at $18.98 on Thursday. The company has a market cap of $4.55 billion, a P/E ratio of -13.65, a P/E/G ratio of 4.27 and a beta of 1.44. Cellebrite DI Ltd. has a 52-week low of $10.25 and a 52-week high of $26.30. The stock’s 50-day simple moving average is $19.86 and its 200 day simple moving average is $19.97.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. As a group, equities analysts predict that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CLBT has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 target price on shares of Cellebrite DI in a report on Wednesday, April 2nd. Lake Street Capital increased their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Finally, JPMorgan Chase & Co. upped their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 11th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Cellebrite DI has an average rating of “Buy” and an average price target of $23.43.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.